Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early anticoagulation strategies after heart valve replacement
ChiCTR1800019841Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Lanzhou University
- Start
- Dec 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of heparin and low molecular weight heparin calcium in Cardiac valve disease (VHD) (3 arms), sponsored by The First Hospital of Lanzhou University. Primary endpoints: Occurrence of bleeding events and Occurrence of thromboembolic events. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
heparinlow molecular weight heparin calcium
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on ChiCTR1800019841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019841.